76
|
Channick R, Chin K, Kim N, McConnell J, Poch D, Flynn M, Leber L, Morganti A, McLaughlin V. P4673Macitentan in chronic thromboembolic pulmonary hypertension (CTEPH): combined data from OPUS and OrPHeUS real-world data sets. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.1055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
The OPsumit® USers Registry (OPUS) provides real-world data in patients (pts) with pulmonary hypertension newly started on macitentan. The OPsumit® Historical USers cohort (OrPHeUS) study was conducted to supplement OPUS to fulfil the FDA request to characterise the safety of macitentan in clinical practice. Both studies included pts with CTEPH.
Purpose
To describe the characteristics and safety outcomes of CTEPH pts newly treated with macitentan.
Methods
OPUS is a prospective, US, multicentre, long-term, observational drug registry (NCT02126943) ongoing since Apr 2014. OrPHeUS was a retrospective, US, multicentre medical chart review (NCT03197688); data collected Oct 2013-Mar 2017. This subgroup analysis describes CTEPH patient characteristics at macitentan initiation, hospitalisations, survival and liver function tests (LFTs) in the combined OPUS/OrPHeUS data set. LFTs are also provided for the OPUS/OrPHeUS pulmonary arterial hypertension (PAH) population.
Results
As of Oct 2018, OPUS/OrPHeUS included 144 CTEPH pts with follow-up data. At macitentan initiation, median (Q1, Q3) age was 66 (56, 73) years; of the 53 pts with a WHO functional class (FC) assessment, 35.8%, 49.1% and 15.1% were in FC II, III and IV, respectively. Median (Q1, Q3) time from CTEPH diagnosis was 18.6 (7.4, 56.4) months (n=141). At macitentan initiation, 32.6% of pts had no PAH therapy, 63.9% were receiving one and 3.5% were receiving two PAH therapies. Median (Q1, Q3) exposure to macitentan was 15.9 (4.3, 30.4) months. There were 43 (29.9%) CTEPH pts who discontinued treatment; 23 due to an adverse event (AE), 0 due to a hepatic AE (HAE) and 20 not due to an AE/HAE. There were 58 (40.3%) CTEPH pts who experienced ≥1 hospitalisation and 9 (6.3%) pts died. LFTs are presented in the table.
LFTs CTEPH follow-up pts PAH follow-up pts (N=144) (N=4072) ALT or AST ≥3x ULN Pts with ≥1 event, n (%) 1 (0.7) 132 (3.2) Incidence rate per 1 person-year (95% CI) 0.005 (0.001, 0.035) 0.024 (0.020, 0.029) ALT or AST ≥3x ULN and total bilirubin ≥2x ULN Pts with ≥1 event, n (%) 1 (0.7) 27 (0.7) Incidence rate per 1 person-year (95% CI) 0.005 (0.001, 0.035) 0.005 (0.003, 0.007) ALT: alanine aminotransferase; AST: aspartate aminotransferase; CI: confidence interval; ULN: upper limit of normal.
Conclusions
Analysis of OPUS/OrPHeUS data provides further insight into real-world use of macitentan in CTEPH pts. The observed hepatic safety profile in CTEPH pts is in line with that of PAH pts.
Acknowledgement/Funding
Actelion Pharmaceuticals Ltd
Collapse
|
77
|
Kim N, Shin S, Ryu Y, Han I, Heo J, Choi D. Prognostic factors for predicting early recurrence within the first year of surgery in pancreatic ductal adenocarcinoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
78
|
Kim N. EP1.01-09 Clinical Efficacy of Circulating Tumor DNA Test in Advanced Non-Small-Cell Lung Cancer Patients Who Might Have T790M Mutation. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
79
|
Kim N, Yoon H, Kim S, Chang J, Suh C. Contribution of ATM Mutation to the Improved Radio-Sensitivity: Retrospective Analysis Using Next-Generation Sequencing Data. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
80
|
Byun H, Kim N, Park S, Seong J. Radiotherapy-Related Lymphopenia in Patients with Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1997] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
81
|
Kim N, Jung Y, Jang J, Cheon D, Koh W, Kim J, Ko J, Ro Y. 563 Incisional biopsy-induced spontaneous regression with halo phenomenon in a congenital melanocytic nevus. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
82
|
Kim N, Cheng J, Huang W, Kimura T, Zeng Z, Kay C, Lee V, Seong J. A Multi-National, Multi-Institutional Study of Comparing an Efficacy of Stereotactic Body Radiation Therapy and Radiofrequency Ablation for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
83
|
Ejaz N, Xu J, Branscheidt M, Hertler B, Schambra H, Widmer M, Faria AV, Harran M, Cortes JC, Kim N, Celnik PA, Kitago T, Luft A, Krakauer JW, Diedrichsen J. Reply: Further evidence for a non-cortical origin of mirror movements after stroke. Brain 2019; 142:e2. [PMID: 30596904 DOI: 10.1093/brain/awy309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
84
|
Tamura Y, Santo M, Araki Y, Matsubayashi H, Takaya Y, Doshida M, Sakaguchi K, Yamaguchi K, Mizuta S, Kim N, Okuno K, Kitaya K, Takeuchi T, Ishikawa T. 29. CHROMOSOMAL COPY NUMBER ANALYSIS OF CHORIONIC VILLUS FROM SPONTANEOUS ABORTION BY NEXT GENERATION SEQUENCING. Reprod Biomed Online 2019. [DOI: 10.1016/j.rbmo.2019.04.082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
85
|
Kim H, Kim N. Scope position is a determining factor for diagnostic performance of EUS-FNA for mass lesions in the pancreas head and uncinate process. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
86
|
Ejaz N, Xu J, Branscheidt M, Hertler B, Schambra H, Widmer M, Faria AV, Harran MD, Cortes JC, Kim N, Celnik PA, Kitago T, Luft AR, Krakauer JW, Diedrichsen J. Evidence for a subcortical origin of mirror movements after stroke: a longitudinal study. Brain 2019; 141:837-847. [PMID: 29394326 PMCID: PMC5837497 DOI: 10.1093/brain/awx384] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2017] [Accepted: 11/23/2017] [Indexed: 01/23/2023] Open
Abstract
Following a stroke, mirror movements are unintended movements that appear in the non-paretic hand when the paretic hand voluntarily moves. Mirror movements have previously been linked to overactivation of sensorimotor areas in the non-lesioned hemisphere. In this study, we hypothesized that mirror movements might instead have a subcortical origin, and are the by-product of subcortical motor pathways upregulating their contributions to the paretic hand. To test this idea, we first characterized the time course of mirroring in 53 first-time stroke patients, and compared it to the time course of activities in sensorimotor areas of the lesioned and non-lesioned hemispheres (measured using functional MRI). Mirroring in the non-paretic hand was exaggerated early after stroke (Week 2), but progressively diminished over the year with a time course that parallelled individuation deficits in the paretic hand. We found no evidence of cortical overactivation that could explain the time course changes in behaviour, contrary to the cortical model of mirroring. Consistent with a subcortical origin of mirroring, we predicted that subcortical contributions should broadly recruit fingers in the non-paretic hand, reflecting the limited capacity of subcortical pathways in providing individuated finger control. We therefore characterized finger recruitment patterns in the non-paretic hand during mirroring. During mirroring, non-paretic fingers were broadly recruited, with mirrored forces in homologous fingers being only slightly larger (1.76 times) than those in non-homologous fingers. Throughout recovery, the pattern of finger recruitment during mirroring for patients looked like a scaled version of the corresponding control mirroring pattern, suggesting that the system that is responsible for mirroring in controls is upregulated after stroke. Together, our results suggest that post-stroke mirror movements in the non-paretic hand, like enslaved movements in the paretic hand, are caused by the upregulation of a bilaterally organized subcortical system.
Collapse
|
87
|
Schambra HM, Xu J, Branscheidt M, Lindquist M, Uddin J, Steiner L, Hertler B, Kim N, Berard J, Harran MD, Cortes JC, Kitago T, Luft A, Krakauer JW, Celnik PA. Differential Poststroke Motor Recovery in an Arm Versus Hand Muscle in the Absence of Motor Evoked Potentials. Neurorehabil Neural Repair 2019; 33:568-580. [PMID: 31170880 DOI: 10.1177/1545968319850138] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Background. After stroke, recovery of movement in proximal and distal upper extremity (UE) muscles appears to follow different time courses, suggesting differences in their neural substrates. Objective. We sought to determine if presence or absence of motor evoked potentials (MEPs) differentially influences recovery of volitional contraction and strength in an arm muscle versus an intrinsic hand muscle. We also related MEP status to recovery of proximal and distal interjoint coordination and movement fractionation, as measured by the Fugl-Meyer Assessment (FMA). Methods. In 45 subjects in the year following ischemic stroke, we tracked the relationship between corticospinal tract (CST) integrity and behavioral recovery in the biceps (BIC) and first dorsal interosseous (FDI) muscle. We used transcranial magnetic stimulation to probe CST integrity, indicated by MEPs, in BIC and FDI. We used electromyography, dynamometry, and UE FMA subscores to assess muscle-specific contraction, strength, and inter-joint coordination, respectively. Results. Presence of MEPs resulted in higher likelihood of muscle contraction, greater strength, and higher FMA scores. Without MEPs, BICs could more often volitionally contract, were less weak, and had steeper strength recovery curves than FDIs; in contrast, FMA recovery curves plateaued below normal levels for both the arm and hand. Conclusions. There are shared and separate substrates for paretic UE recovery. CST integrity is necessary for interjoint coordination in both segments and for overall recovery. In its absence, alternative pathways may assist recovery of volitional contraction and strength, particularly in BIC. These findings suggest that more targeted approaches might be needed to optimize UE recovery.
Collapse
|
88
|
Kim N, Welty S, Reza T, Sears D, McFarland W, Raymond HF. Undiagnosed and Untreated HIV Infection Among Persons Who Inject Drugs: Results of Three National HIV Behavioral Surveillance Surveys, San Francisco, 2009-2015. AIDS Behav 2019; 23:1586-1589. [PMID: 30259347 DOI: 10.1007/s10461-018-2284-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
We examined three waves of National HIV Behavioral Surveillance surveys of persons who inject drugs (PWID) in San Francisco to assess meeting UNAIDS 90-90-90 targets. Diagnosis of PWID living with HIV increased from 64.4% in 2009 to 80.5% in 2015. Antiretroviral treatment among those diagnosed did not improve (63.8% in 2009, 62.9% in 2015). Programs in San Francisco have not achieved the first two UNAIDS targets for PWID by 2015. In a context of a rising opioid epidemic, there is urgent need for increased case finding of PWID living with HIV who are undiagnosed with rapid linkage to treatment.
Collapse
|
89
|
Goldstein S, Goldstein I, Kim N, Kellogg Spadt S, Murina F. 022 Three Site, Prospective, Double-blind, Sham-Controlled Proof-of-Principle Study of the Safety and Efficacy of CO2 Fractional Laser Therapy in Women with Vestibulodynia: An Interim Analysis. J Sex Med 2019. [DOI: 10.1016/j.jsxm.2019.03.479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
90
|
Wardak Z, Bland R, Ahn C, Xie XJ, Chason D, Morrill K, Stehel E, Nedzi L, Ding C, Medin P, Boike T, Abdulrahman R, Folkert M, Iyengar P, Kim N, Choy H, Bagley C, Timmerman R. A Phase 2 Clinical Trial of SABR Followed by Immediate Vertebroplasty for Spine Metastases. Int J Radiat Oncol Biol Phys 2019; 104:83-89. [DOI: 10.1016/j.ijrobp.2019.01.072] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2018] [Revised: 12/27/2018] [Accepted: 01/13/2019] [Indexed: 10/27/2022]
|
91
|
You MW, Kim N, Choi HJ. The value of quantitative CT texture analysis in differentiation of angiomyolipoma without visible fat from clear cell renal cell carcinoma on four-phase contrast-enhanced CT images. Clin Radiol 2019; 74:547-554. [PMID: 31010583 DOI: 10.1016/j.crad.2019.02.018] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Accepted: 02/20/2019] [Indexed: 02/07/2023]
Abstract
AIM To investigate the diagnostic performance and usefulness of texture analysis in differentiating angiomyolipoma (AML) without visible fat from clear cell renal cell carcinoma (ccRCC) on four-phase contrast-enhanced computed tomography (CECT). MATERIALS AND METHODS Seventeen patients with AML without visible fat and 50 patients with ccRCC of size ≤4.5 cm who had also undergone preoperative four-phase CECT were included in this study. The histogram, grey-level co-occurrence matrix (GLCM), and grey-level run length matrix (GLRLM) were evaluated. Sequential feature selection (SFS) and support vector machine (SVM) classifier with leave-one-out cross validation were used. RESULTS Using the SFS and SVM classifiers, five texture features were selected; mean (unenhanced), standard deviation (unenhanced and excretory), cluster prominence (nephrographic), and long-run high grey-level emphasis (corticomedullary). Diagnostic performance of the five selected texture features for all CT phases was as follows: 82% sensitivity, 76% specificity, 85% accuracy, and 85 area under the receiver operating characteristic curve (AUC). In the subgroup analysis, the AUCs of each phase were significantly >0.5 (p<0.05). In the pairwise comparison of AUCs between four phases, there were no significant differences between the four phases except the unenhanced and corticomedullary phases (p=0.015), i.e., the unenhanced phase showed slightly higher AUC than the corticomedullary phase. CONCLUSIONS Texture analysis of small renal masses (≤4.5 cm) on four-phase CECT can accurately differentiate AML without visible fat from ccRCC and showed good diagnostic performance for both the unenhanced and enhanced phases.
Collapse
|
92
|
Yun EJ, Lin CJ, Dang A, Hernandez E, Guo J, Chen WM, Allison J, Kim N, Kapur P, Brugarolas J, Wu K, He D, Lai CH, Lin H, Saha D, Baek ST, Chen BPC, Hsieh JT. Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation. Clin Cancer Res 2019; 25:4542-4551. [PMID: 31000589 DOI: 10.1158/1078-0432.ccr-18-3004] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Revised: 01/21/2019] [Accepted: 04/15/2019] [Indexed: 12/24/2022]
Abstract
PURPOSE Renal cell carcinoma (RCC) is known to be highly radioresistant but the mechanisms associated with radioresistance have remained elusive. We found DOC-2/DAB2 interactive protein (DAB2IP) frequently downregulated in RCC, is associated with radioresistance. In this study, we investigated the underlying mechanism regulating radioresistance by DAB2IP and developed appropriate treatment. EXPERIMENTAL DESIGN Several RCC lines with or without DAB2IP expression were irradiated with ionizing radiation (IR) for determining their radiosensitivities based on colony formation assay. To investigate the underlying regulatory mechanism of DAB2IP, immunoprecipitation-mass spectrometry was performed to identify DAB2IP-interactive proteins. PARP-1 expression and enzymatic activity were determined using qRT-PCR, Western blot analysis, and ELISA. In vivo ubiquitination assay was used to test PARP-1 degradation. Furthermore, in vivo mice xenograft model and patient-derived xenograft (PDX) model were used to determine the effect of combination therapy to sensitizing tumors to IR. RESULTS We notice that DAB2IP-deficient RCC cells acquire IR-resistance. Mechanistically, DAB2IP can form a complex with PARP-1 and E3 ligases that is responsible for degrading PARP-1. Indeed, elevated PARP-1 levels are associated with the IR resistance in RCC cells. Furthermore, PARP-1 inhibitor can enhance the IR response of either RCC xenograft model or PDX model. CONCLUSIONS In this study, we unveil that loss of DAB2IP resulted in elevated PARP-1 protein is associated with IR-resistance in RCC. These results provide a new targeting strategy to improve the efficacy of radiotherapy of RCC.
Collapse
|
93
|
Nishiyama R, Kitaya K, Takaya Y, Yamaguchi K, Kim N, Matsubayashi H, Ishikawa T. Successful ongoing pregnancy following cryopreserved-thawed blastocyst transfer in an infertile Kallmann syndrome woman with balanced reciprocal translocation: a case report. CLIN EXP OBSTET GYN 2019. [DOI: 10.12891/ceog4576.2019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
94
|
Biewenga E, Aisen C, Nguyen T, Gabrielson A, Kim N, Goldstein I. 259 Erectile Dysfunction in an Adolescent with Non-Hodgkin Lymphoma Following Chemotherapy with Agents Known to Induce Cardiac Fibrosis/Myocardial Necrosis: A Case Report and Literature Review. J Sex Med 2019. [DOI: 10.1016/j.jsxm.2019.01.265] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
95
|
Channick R, Chin K, Kim N, Brand M, Morganti A, Selej M, McLaughlin V. Patient Characteristics and Treatment Patterns with Macitentan in Pulmonary Arterial Hypertension: Insights from the OPUS Registry. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.1245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
96
|
Channick R, McLaughlin V, Chin K, McConnell J, Poch D, Brand M, Selej M, Morganti A, Kim N. Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Real-World Experience with Macitentan. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.1229] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
97
|
Ko B, Kim N, Seo J, Kim H, Gong G, Kim S, Son B, Ahn SH. Abstract P3-13-01: Application of supine MRI-based 3D printing breast surgical guide for precision breast-conserving surgery. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-13-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
If the size of the tumor is large, neoadjuvant systemic therapy (NST) is performed to reduce the size of the tumor and to conserve the breast. It is known that magnetic resonance imaging is more accurate than mammography (MMG) or ultrasonography (USG) in determining the area of residual cancer in breast-conserving surgery (BSG) after NST. However, there are some problems when performing BCS using MRI. Because the posture of MRI test is different from the posture at surgery, it is difficult to accurately mark the area of the tumor observed in MRI. Neoadjuvant systemic therapy reduces tumor size and often makes it difficult to detect the original tumor area on preoperative MRI. Even if the tumor is not visible in the image, the cancer cells may remain, so it is important to accurately indicate the extent of the initial tumor and remove it. Until now, however, there has been no way to accurately mark past breast tumors in the breast. We have developed a breast surgical guide (BSG) that can mark a range of tumor directly on the breast using three-dimensional printing technology based on supine MRI. This study analyzed the results of patients who underwent BCS using a 3D printing breast surgical guide (3D-BSG) based on supine MRI.
Methods
This trial was designed as a prospective single-institution cohort study. Our study protocol was approved by the Institutional Review Board of Asan Medical Center, Seoul, Korea (IRB No. 2016-1237). Patients who were expected to undergo BCS after NST were enrolled in this study and supine MRI was performed before and after NST. From MRI images, morphological shapes of breasts and tumors were modeled. The prepared digital model was saved in stereolithography file format and then exported to a 3D printer. 3D-BSG is designed to be able to mark the skin and attach the dye injecting column to mark the around the tumor. The breast tissue was removed with blue dye on the basis of the border. To obtain tumor free margin, intraoperative frozen sections were identified in several cavities and re-excision was performed if tumor positive.
Results
Between January 2016 and May 2017, 50 patients were enrolled in the study. BCS was applied to 40 patients, except for those who were rejected or mastectomy. Complete remission was observed in 15 patients after NST. Four patients had tumor positive on resection margins on frozen biopsy during operation, two with IDC and two with DCIS. Re-excision was performed in these patients and tumor negative margin was confirmed in all patients in the final pathology results. The median size of the long axis of the tumor was 1.7 cm (range, 0.5 to 4.5 cm) and the median size of the long axis of the removed breast tissue was 5.1 cm (range, 2.3 to 8.1 cm). The distance between tumor and resection margin was 1.2 cm (range, 0.1 to 4.8 cm)..
Conclusions
In BCS, the application of the supine MRI based 3D-BSG showed low rates of positive margins. Unlike conventional localization techniques, application of 3D-BSG does not cause pain to the patient, has no radiation exposure, and has no time required for the localization procedure, so it will be helpful for patients in BCS in the future.
Citation Format: Ko B, Kim N, Seo J, Kim H, Gong G, Kim S, Son B, Ahn SH. Application of supine MRI-based 3D printing breast surgical guide for precision breast-conserving surgery [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-13-01.
Collapse
|
98
|
Esteva FJ, Lee S, Yu S, Kim M, Kim N, Stebbing J. Abstract P6-17-03: 24 months results from a double-blind, randomized phase III trial comparing the efficacy and safety of neoadjuvant then adjuvant trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-17-03] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background CT-P6 is a proposed biosimilar to reference trastuzumab (RTZ). A double-blind, randomized, phase III trial showed similar efficacy and safety for CT-P6 and RTZ in HER2 positive EBC (NCT02162667). The primary endpoint, pathological complete response rate was within the predefined margin to demonstrate similarity (Lancet Oncol 2017). Safety and efficacy at 1 year (ESMO 2017), and cardiac toxicity at a median of 19 months (SABCS 2017) were similar between the two treatment groups. Here we report updated disease-free survival (DFS), overall survival (OS) and cardiac toxicity data with a median follow-up of 2 years.
Methods A total of 549 patients with HER2 positive EBC were randomized to receive CT-P6 (n=271) or RTZ (n=278) in combination with docetaxel (Cycles 1-4) and 5-fluorouracil, epirubicin and cyclophosphamide (Cycles 5-8). CT-P6 or RTZ was administered at 8 mg/kg (Cycle 1 only) followed by 6 mg/kg every 3 weeks. After surgery, patients received CT-P6 or RTZ monotherapy then entered the follow-up period up to 3 year of last patient enrollment. Time to event analyses were performed using Cox regression and Kaplan-Meier methods.
Results A total of 528 patients (259/271 in CT-P6 and 269/278 in RTZ) entered the follow-up period after completing therapy. The median follow-up duration was over 27 months. The number of DFS events (32 [12.4%] in CT-P6 and 26 [10.0%] in RTZ) and OS events (14 [5.2%] in CT-P6 and 12 [4.3%] in RTZ) were comparable in the ITT set. Additionally, DFS and OS were similar between CT-P6 group and RTZ group in both the per-protocol set (PPS) and the ITT set. In the ITT set, the proportion of 2-year DFS (95% CI) was 86% (80% – 90%) in CT-P6 and 90% (85% – 93%) in RTZ. The proportion of 2-year OS was 97% (93% – 98%) in CT-P6 and 98% (96% – 99%) in RTZ. Median DFS and OS have not been reached. After 1-year treatment, no new cases of heart failure were reported during the follow-up period. Left ventricular ejection fraction (LVEF) was similar in both groups (mean LVEF, more than 60%).
Table 1.Summary of Long Term Efficacy Endpoints PPSITT set CT-P6 (n=248)Reference Trastuzumab (n=256)CT-P6 (n=258)Reference Trastuzumab (n=261)Proportion of DFS1 year (95% CI)0.95 (0.91 – 0.97)0.96 (0.93 – 0.98)0.95 (0.91 – 0.97)0.96 (0.93 – 0.98)2 years (95% CI)0.86 (0.80 – 0.90)0.90 (0.85 – 0.93)0.86 (0.80 – 0.90)0.90 (0.85 – 0.93)p-value0.33240.3085 CT-P6 (n=248)Reference Trastuzumab (n=256)CT-P6 (n=271)Reference Trastuzumab (n=278)Proportion of OS1 year (95% CI)1.00 (1.00 – 1.00)1.00 (0.97 – 1.00)0.99 (0.97 – 1.00)0.99 (0.97 – 1.00)2 year (95% CI)0.97 (0.94 – 0.99)0.98 (0.96 – 0.99)0.97 (0.93 – 0.98)0.98 (0.96 – 0.99)3 year (95% CI)0.94 (0.88 – 0.97)0.93 (0.86 – 0.96)0.92 (0.86 – 0.96)0.93 (0.87 – 0.96)p-value0.93290.5057
Conclusions The efficacy and cardiac toxicity profile between CT-P6 and RTZ in EBC patients were consistent with published data. Time to event analyses as secondary efficacy endpoints supported the similarity for the two study drugs. CT-P6 was consistently well tolerated with a similar cardiotoxicity profile to that of RTZ through long duration of follow-up.
Citation Format: Esteva FJ, Lee S, Yu S, Kim M, Kim N, Stebbing J. 24 months results from a double-blind, randomized phase III trial comparing the efficacy and safety of neoadjuvant then adjuvant trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-03.
Collapse
|
99
|
Kim N, Park D, Ryu Y, Han I, Choi S, Choi D, Heo J. Validation of AJCC 8th edition stage for Gall bladder cancer. Eur J Surg Oncol 2019. [DOI: 10.1016/j.ejso.2018.10.254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
100
|
Cho HJ, Yoon JY, Kim N, Jang SY, Bae MH, Lee JH, Yang DH, Park HS, Cho Y, Chae SC. Predictive value of a fragmented QRS complex in diagnosing patients with myocardial ischemia. Clin Cardiol 2019; 42:379-384. [PMID: 30597592 PMCID: PMC6712309 DOI: 10.1002/clc.23148] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/02/2018] [Accepted: 12/27/2018] [Indexed: 11/26/2022] Open
Abstract
Background A fragmented QRS complex (fQRS) is caused by conduction abnormalities of the ventricle secondary to myocardial ischemia and/or scar in patients with myocardial infarction. However, the implications of the fQRS in the development of coronary artery disease with myocardial ischemia in those without a scar remain unknown. Methods We studied electrocardiograms (ECGs) obtained from 150 patients (60.5 ± 8.5 years, 102 men) with myocardial ischemia, which was confirmed by performing both, a nuclear exercise stress test and coronary angiography. We also studied ECGs obtained from 601 patients (58.5 ± 10.0 years, 315 men) who showed a negative nuclear exercise stress test (control group). Patients in whom the nuclear exercise stress test showed a myocardial scar were excluded. Results An fQRS was more commonly observed in patients with myocardial ischemia (n = 48, 32.0%) than in the control group (n = 133, 22.1%) (P = 0.011). The sensitivity, specificity, positive, and negative predictive values of fQRS in diagnosing myocardial ischemia were 32.0, 77.9, 26.5, and 82.1%, respectively. The fQRS (odds ratio 1.580, 95% confidence interval 1.020‐2.446, P = 0.040) was an independent predictor of myocardial ischemia after adjusting for age, sex, current smoking habits, ST‐T changes on ECG, as well as histories of hypertension, diabetes, and dyslipidemia. Moreover, the fQRS showed an incremental prognostic value over conventional risk factors (χ2 = 5, P = 0.032) and over a combination of conventional factors and ST‐T changes (χ2 = 9, P = 0.014). Conclusions The fQRS is a moderately sensitive and independent predictor of myocardial ischemia.
Collapse
|